"Better Than Nothing" Doesn't Cut It for Zalicus

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

First, the good news: In a phase 2b trial, Zalicus' (Nasdaq: ZLCS  ) Synavive passed its primary endpoint, improving patients' rheumatoid arthritis symptoms compared with placebo.

Despite the seemingly good news, Zalicus has decided to stop development of the drug.

For indications with high unmet need, beating placebo is usually good enough. But for diseases such as rheumatoid arthritis, being better than placebo just doesn't cut it. There are too many other options for patients.

In addition to being compared to placebo, Synavive was compared to its individual components -- prednisolone and dipyridamole -- as well as prednisolone, another drug commonly prescribed for rheumatoid arthritis. Unfortunately, the combination product didn't perform any better than prednisolone alone.

The company didn't release any information about whether Synavive beat the other active comparators, but it really doesn't matter. Even if the Food and Drug Administration would approve Synavive with just placebo data, no doctor would prescribe it if it isn't any better than prednisolone, which is available as a generic. Shelving the drug is really Zalicus' best move.

This bad news could be good for Pfizer (NYSE: PFE  ) , Incyte (Nasdaq: INCY  ) , and Rigel, which are all developing oral rheumatoid arthritis drugs that might have competed with Synavive. Pfizer is waiting to hear from the FDA on or before Nov. 21 about its drug tofacitinib. Incyte, with partner Eli Lilly (NYSE: LLY  ) , and Rigel (partnered with AstraZeneca (NYSE: AZN  ) ) aren't much further behind.

Losing its lead pipeline drug is a big hit for Zalicus; shares are down about 40% on the news. The company will need to hunker down and focus of its other pain medications: Z160, which just entered a phase 2 trial, and Z944 that's a little further behind. Without any major catalysts for about a year, investors buying the drop today have to be willing to hold for awhile.

The biggest binary event, the presidential election, is around the corner. Check out the Fool's new free report, "These Stocks Could Skyrocket After the 2012 Presidential Election," where you'll get ideas for companies that can benefit from each candidate's platform. Get your free copy by clicking here.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2011827, ~/Articles/ArticleHandler.aspx, 10/24/2016 12:39:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,226.01 80.30 0.44%
S&P 500 2,148.87 7.71 0.36%
NASD 5,300.87 43.47 0.83%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 12:19 PM
EPRSQ $0.03 Up +0.00 +0.80%
EPIRUS Biopharmace… CAPS Rating: ****
AZN $30.15 Down -0.57 -1.84%
AstraZeneca CAPS Rating: ****
INCY $88.23 Up +0.51 +0.58%
Incyte CAPS Rating: **
LLY $78.24 Down -0.01 -0.01%
Eli Lilly and Co. CAPS Rating: ***
PFE $32.23 Up +0.05 +0.16%
Pfizer CAPS Rating: ****